Evidence map›Paper›PMID 37971074›Full record

ArticleJournal of biomedical materials research. Part A2024

Extrusion 3D-printing and characterization of poly(caprolactone fumarate) for bone regeneration applications.

Bipin Gaihre, Maria D Astudillo Potes, Xifeng Liu, Maryam Tilton, Emily Camilleri, Asghar Rezaei, Vitalii Serdiuk, Sungjo Park, Fabrice Lucien, Andre Terzic and 1 more

Abstract read
In one paragraph

Article in Journal of biomedical materials research. Part A, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Biodegradable poly(caprolactone fumarate) 3D printed scaffolds for segmental bone defects within the Masquelet technique.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bipin GaihreDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0009-0000-2596-7427
Maria D Astudillo PotesDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Xifeng LiuDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Maryam TiltonDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Emily CamilleriDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Asghar RezaeiDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Vitalii SerdiukDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
Sungjo ParkDepartment of Cardiovascular Diseases and Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Fabrice LucienDepartment of Urology, Mayo Clinic, Rochester, Minnesota, USA.
Andre TerzicDepartment of Cardiovascular Diseases and Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Lichun LuDepartment of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.

Funding

Musculoskeletal Research Training ProgramT32AR056950 · NIAMS · MAYO CLINIC ROCHESTER · PI Jennifer J Westendorf · 2009 to 2026
$7.0M
Metastatic Spine Tumors: Minimally Invasive Fracture Risk Analysis and Treatment - MasterR01AR056212 · NIAMS · MAYO CLINIC ROCHESTER · PI Benjamin D Elder, Lichun Lu · 2008 to 2026
$6.2M
Injectable and Moldable Composite Bone Scaffolds for Spinal FusionR01AR075037 · NIAMS · MAYO CLINIC ROCHESTER · PI ELDER, BENJAMIN D, LU, LICHUN · 2019 to 2023
$2.5M
NIAMS NIH HHS R01 AR056212NIAMS NIH HHS R01 AR075037NIAMS NIH HHS T32 AR056950NIH HHS R01 AR75037 and AR56212
6 · The paper itself

Abstract

Polycaprolactone fumarate (PCLF) is a cross-linkable PCL derivative extensively considered for tissue engineering applications. Although injection molding has been widely used to develop PCLF scaffolds, platforms developed using such technique lack precise control on architecture, design, and porosity required to ensure adequate cellular and tissue responses. In particular, the scaffolds should provide a suitable surface for cell attachment and proliferation, and facilitate cell-cell communication and nutrient flow. 3D printing technologies have led to new architype for biomaterial development with micro-architecture mimicking native tissue. Here, we developed a method for 3D printing of PCLF structures using the extrusion printing technique. The crosslinking property of PCLF enabled the unique post-processing of 3D printed scaffolds resulting in highly porous and flexible PCLF scaffolds with compressive properties imitating natural features of cancellous bone. Generated scaffolds supported excellent attachment and proliferation of mesenchymal stem cells (MSC). The high porosity of PCLF scaffolds facilitated vascularized membrane formation demonstrable with the stringency of the ex ovo chicken chorioallantoic membrane (CAM) implantation. Furthermore, upon implantation to rat calvarium defects, PCLF scaffolds enabled an exceptional new bone formation with a bone mineral density of newly formed bone mirroring native bone tissue. These studies suggest that the 3D-printed highly porous PCLF scaffolds may serve as a suitable biomaterial platform to significantly expand the utility of the PCLF biomaterial for bone tissue engineering applications.

Indexed as

FumaratesTissue ScaffoldsAnimalsBiocompatible MaterialsBone RegenerationPolyestersPorosityPrinting, Three-DimensionalRatsTissue EngineeringBiocompatible MaterialsFumaratespoly(caprolactone fumarate)Polyestersbone tissue engineeringextrusion printingpolycaprolactone fumarateporosity

Identifiers

PMID37971074
PMCPMC10948318

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.